Molecular Characterization of Beta-lactams Resistance in Pseudomonas aeruginosa Isolated from Clinical Sources at the Nairobi Hospital

The increase of Beta-lactamases producing organisms can cause major therapeutic failure and poses a significant clinical challenge in healthcare settings.  A total of 185 clinical isolates of Pseudomonas aeruginosa strains were collected from in-and out-patients at The Nairobi Hospital, 74.1 % were inpatients and 25.9% were outpatients with the high prevalence of this bacterium among the male gender (61.1%) than female(38.9%); and preponderantly comprising the patients above 45 years old (64.3%). The highest numbers of P. aeruginosa were isolated from pus swab (39.5%), respiratory secretions (25.9%), and urine (18.9%). The resistance rate of P. aeruginosa against carbapenem was 31.5% among the isolates. The prevalence of MBL producing P. aeruginosa was 22.7% as compared to non-MBL isolates (77.3%). The MBL isolates were resistant to the examined antibiotics. There were two predominant genes VIM-2 (28.57%) and NDM-1 (66.67%) types among MBL P. aeruginosa, and more prevalent genes were isolated from Critical care nursing ward; Intensive Care Unit (45.2%) and High Dependency Unite (28.6%) at The Nairobi Hospital. These findings suggest that the early detection of   Metallo-Beta-Lactamases-producing isolates and the cooperation between medical professionals and infection control team may help in appropriate antimicrobial therapy and avoid further spread of these multidrug resistance strains. Keywords: Pseudomonas aeruginosa, Metallo-Beta-Lactamases, Resistance, Beta-lactams

Genomic surveillance of severe acute respiratory syndrome coronavirus 2 in Burundi, from May 2021 to January 2022

Abstract Background The emergence and rapid spread of new severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) variants have challenged the control of the COVID-19 pandemic globally. Burundi was not spared by that pandemic, but the genetic diversity, evolution, and epidemiology of those variants in the country remained poorly understood. The present study sought to investigate the role of different SARS-COV-2 variants in the successive COVID-19 waves experienced in Burundi and the impact of their evolution on the course of that pandemic. We conducted a cross-sectional descriptive study using positive SARS-COV-2 samples for genomic sequencing. Subsequently, we performed statistical and bioinformatics analyses of the genome sequences in light of available metadata. Results In total, we documented 27 PANGO lineages of which BA.1, B.1.617.2, AY.46, AY.122, and BA.1.1, all VOCs, accounted for 83.15% of all the genomes isolated in Burundi from May 2021 to January 2022. Delta (B.1.617.2) and its descendants predominated the peak observed in July–October 2021. It replaced the previously predominant B.1.351 lineage. It was itself subsequently replaced by Omicron (B.1.1.529, BA.1, and BA.1.1). Furthermore, we identified amino acid mutations including E484K, D614G, and L452R known to increase infectivity and immune escape in the spike proteins of Delta and Omicron variants isolated in Burundi. The SARS-COV-2 genomes from imported and community-detected cases were genetically closely related. Conclusion The global emergence of SARS-COV-2 VOCs and their subsequent introductions in Burundi was accompanied by new peaks (waves) of COVID-19. The relaxation of travel restrictions and the mutations occurring in the virus genome played an important role in the introduction and the spread of new SARS-COV-2 variants in the country. It is of utmost importance to strengthen the genomic surveillance of SARS-COV-2, enhance the protection by increasing the SARS-COV-2 vaccine coverage, and adjust the public health and social measures ahead of the emergence or introduction of new SARS-COV-2 VOCs in the country